Hitachi Medical Systems Europe Holding AG
Storys zum Thema Pharmakologie
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
- 2mehr
- 2
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®
mehr Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins
Ein DokumentmehrEuropean Association of E-Pharmacies (EAEP)
EAEP as a Driving Force and Think Tank: European Association of Online Pharmacies Repositions Itself
Brussels/Berlin (ots) - The leading association of European online pharmacies has a new board team, a new name and a new external image: Walter Hess, Head Germany in the Group Management of the Zur Rose Group and CEO of DocMorris N.V., is now president of the association and Stefan Feltens, CEO SHOP APOTHEKE EUROPE, ...
mehrEuropean Society for Medical Oncology (ESMO)
Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-Breaking Cancer Research
mehrTechnische Universität München
New synthetic peptides could attenuate atherosclerosis
Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36446/ NEWS RELEASE New synthetic peptides could attenuate atherosclerosis Synthetic “mini” receptors block atherosclerosis Atherosclerosis, a lipid-triggered chronic inflammatory disease of our arteries, is the main cause of strokes and ...
mehr
- 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
Ein Dokumentmehr Merger: Newly-formed Semdor Pharma Group becomes one of Europe's leading pharmaceutical companies for narcotics and medical cannabis
mehrEleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member
Freiburg (ots) - Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to ...
mehrSysmex Inostics Presents Data at the American Society of Hematology Annual Meeting Demonstrating Exquisite Sensitivity of SafeSEQ NGS Technology for Detection of Measurable Residual Disease in Acute Myeloid Leukemia
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based, high-sensitivity molecular testing for oncology, is presenting the poster "Ultrasensitive Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML) Using a Targeted Next Generation Sequencing (NGS) Panel" at ...
mehr- 5
Commemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups
Ein Dokumentmehr Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine
mehr
EvoBiotiX collaborates with Boehringer Ingelheim and the University of Salzburg on naturally derived Extracellular Vesicles (EVs)
Salzburg/Melide(CH) (ots) - Swiss Biotech EvoBiotiX SA today announced a multi-year collaboration with Boehringer Ingelheim in the field of naturally derived EVs. A significant part of this program will fund research of the drug delivery potential of naturally derived EVs in the group of Prof. Meisner-Kober at the ...
mehrTechnische Universität München
Fighting corona with machine learning
Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36254/ NEWS RELEASE The Bavarian Research Foundation is funding five TUM-research projects on Covid-19 Fighting corona with machine learning The Technical University of Munich (TUM) is starting five new research projects that focus on the ...
mehrTechnische Universität München
An alternative to animal experiments - New applications for organoids from human intestinal tissue
Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36252/ Images for journalists: https://mediatum.ub.tum.de/1576619 NEWS RELEASE New applications for organoids from human intestinal ...
mehrRegulatory breakthrough for BrainRepair UG start-up - Stem cell treatment for newborns /EMA Orphan Drug Designation is followed by agreement on Paediatric Investigation Plan
mehrTechnische Universität München
Finding cortisone alternatives with fewer side effects
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/die-tum/aktuelles/pressemitteilungen/details/36207/ Images for journalists: https://mediatum.ub.tum.de/1559845 NEWS RELEASE DNA binding is essential for effectiveness of steroids Finding cortisone alternatives with fewer side effects Many people use ...
mehrSysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy
Baltimore, MD (ots) - Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating RAS mutation status in circulating tumor DNA (ctDNA) of colorectal cancer (CRC) patients undergoing anti-EGFR ...
mehr
KOPIE VON: Inspirational talks form SIRION Biotech, CLS Behring and the German Accelerator at the 13th Biotech Press Lounge at the IZB
Ein DokumentmehrSysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing
Baltimore, Maryland (ots) - Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a clinical study evaluating the performance of plasma RAS mutation testing with OncoBEAM RAS CRC as compared to standard of care ...
mehrVersameb raises CHF 6 million and strengthens team to advance its VERSagile technology platform towards clinical trials
Basel, Switzerland (ots) - Versameb AG, a biopharmaceutical company developing innovative ribonucleic acid (RNA) therapeutics, announced today the closing of a CHF 6 million seed financing round. Versameb further strengthens its team by the appointment of Dr. Klaas P. Zuideveld as Chief Development Officer effective ...
mehrHauck Aufhäuser Lampe Privatbank AG
ÓSKARE CAPITAL SAS launches ÓSKARE Fund I focusing on innovative European companies in the medical cannabinoid industry
Paris, FRANCE & Dublin, IRELAND (ots) - ÓSKARE CAPITAL SAS today launches ÓSKARE Fund I together with cannabinoid industry veteran Bruce Linton. The EU based fund targets next generation cannabinoid therapies and related industry infrastructure, leveraging the expertise and track record of the founding team in ...
mehrHAPA pharm receives GMP certification / Quality assured medical cannabis products
Dortmund (ots) - HAPA pharm ("HAPA" or the "Company") operates production facilities in North Macedonia to grow and process medical cannabis for the sale of pharmaceutical cannabis flos and extracts. On May 1st 2020, the Company has successfully received GMP (Good Manufacturing Practice) approval for both facilities. This milestone demonstrates HAPA's commitment ...
mehr- 2
Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation
mehr
Eleva's drug candidate to be examined for use in Covid-19 treatment
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is exploring the potential of one of its drug candidates for first-in-line therapy of Covid-19. The compound, factor H, is part of the complement system, which is believed to affect the severity of the course of Covid-19. Eleva has developed factor H previously for a different indication and taken it through ...
mehrTechnische Universität München
A disease trigger for pancreatitis has been identified
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161/ 71-5403 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36036/ High resolution images: https://mediatum.ub.tum.de/1545776 NEWS RELEASE A Calcium channel is involved in the development of pancreatitis A disease trigger for pancreatitis has been identified One factor ...
mehrSysmex Inostics' updated SafeSEQ Breast Cancer Panel advances novel clinical uses of ctDNA through quantitative testing
Baltimore, Maryland (ots) - Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer Research 2019 annual meeting, Sysmex Inostics has updated the test to provide additional key information for investigation of the validity ...
mehrTechnische Universität München
Active droplets: Long-lasting and precise dosing of medication thanks to an oil-hydrogel mixture
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35918/ High resolution images: https://mediatum.ub.tum.de/1538709 NEWS RELEASE Active droplets Long-lasting and precise dosing of medication thanks to an ...
mehrTechnische Universität München
Major project for Munich neurosciences
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 8161 71 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35908/ High resolution images: https://mediatum.ub.tum.de/1537625 NEWS RELEASE CLINSPECT-M: Clinical mass spectrometry center for molecular brain research Major project for Munich neurosciences In a joint ...
mehrSysmex Inostics and Oxford Gene Technology plasma and tissue sequencing show clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment
Hamburg, Germany and Baltimore, Maryland (ots) - Pathologist Dr. Vincente Peg of the Vall d´Hebron University Hospital (Barcelona Spain) and colleagues have presented a correlation between the clearance of circulating tumor DNA (ctDNA) in HER2-positive or triple-negative breast cancer patients undergoing ...
mehr